Literature DB >> 16080493

Are factor V and prothrombin mutations associated with increased risk of oral cancer?

Eleftherios Vairaktaris1, Christos Yapijakis, Jörg Wiltfang, Jutta Ries, Antonis Vylliotis, Spyridoula Derka, Stavros Vasiliou, Friedrich W Neukam.   

Abstract

BACKGROUND: Methylenetetrahydrofolate reductase is associated with pathogenesis of both thrombosis and oral cancer. Therefore, a search for a similar association of other thrombosis-related factors with oral cancer is justified. PATIENTS AND METHODS: In order to investigate whether the coagulation factor V Leiden and prothrombin G20210A mutations increase the risk of oral cancer, we searched for these mutant alleles by RFLP analysis in DNA samples of 102 patients with oral cancer and 120 healthy controls.
RESULTS: Neither the Leiden nor the G20210A alleles were found in statistically different frequencies in the two groups. In addition, no statistical difference was observed in parameters such as sex, age and positive family history for cancer. Nevertheless, a significant difference was observed for Leiden in patients with a positive history for thrombophilia (p < 0.001).
CONCLUSION: There seems to be no association of prothrombin, and possibly a minor contribution of factor V, in oncogenesis in the oral region.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16080493

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Malignancy and hypercoagulability: a two-way association revisited.

Authors:  Elie G Aoun; Khaled M Musallam; Mohamad Abou-Ghazal; Ali T Taher
Journal:  J Thromb Thrombolysis       Date:  2010-10       Impact factor: 2.300

2.  Association of Interleukin-10 (A1082G) gene polymorphism with Oral squamous cell carcinoma in north Indian population.

Authors:  Syed Rizwan Hussain; Mohammad Kaleem Ahmad; Abbas Ali Mahdi; Hena Naqvi; Mohammad Waseem Ahmad; Saurabh Srivastava; Kumud Nigam; Shalini Gupta
Journal:  J Genet       Date:  2016-06       Impact factor: 1.166

3.  Methylenetetrahydrofolate reductase polymorphism and minor increase of risk for oral cancer.

Authors:  E Vairaktaris; C Yapijakis; P Kessler; A Vylliotis; J Ries; J Wiltfang; S Vassiliou; S Derka; F W Neukam
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-20       Impact factor: 4.553

4.  Factor V Leiden 1691G/A and prothrombin gene 20210G/A polymorphisms as prothrombotic markers in adult Egyptian acute leukemia patients.

Authors:  Azza Hamdy El Sissy; Maha H El Sissy; Shereef Elmoamly
Journal:  Med Oncol       Date:  2014-09-27       Impact factor: 3.064

5.  Thrombophilic polymorphisms are not associated with disease-free survival in breast cancer patients.

Authors:  Aydan Eroğlu; Ayfer Ezgi Yılmaz; Durdu Karasoy
Journal:  Int J Clin Exp Med       Date:  2015-05-15

6.  Risk of prostate cancer and thrombosis-related factor polymorphisms.

Authors:  Somayehsadat Ghasemi; Aydin Tavakoli; Mohamad Moghadam; Mohamad Ali Zargar; Maryam Abbaspour; Nasim Hatamnejadian; Ahmad Ebrahimi
Journal:  Biomed Rep       Date:  2013-10-04

7.  Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study.

Authors:  Mari Tinholt; Marte Kathrine Viken; Anders Erik Dahm; Hans Kristian Moen Vollan; Kristine Kleivi Sahlberg; Oystein Garred; Anne-Lise Børresen-Dale; Anne Flem Jacobsen; Vessela Kristensen; Ida Bukholm; Rolf Kåresen; Ellen Schlichting; Grethe Skretting; Benedicte Alexandra Lie; Per Morten Sandset; Nina Iversen
Journal:  BMC Cancer       Date:  2014-11-19       Impact factor: 4.430

8.  Inherited thrombophilia in a patient with colorectal carcinoma.

Authors:  Matej Hrnčár; Jozef Breznický; Juraj Chudej; Juraj Sokol; Ján Staško
Journal:  Prz Gastroenterol       Date:  2019-07-17

9.  Identification of F5 as a Prognostic Biomarker in Patients with Gastric Cancer.

Authors:  Yi Liu; Xi-Wen Liao; Yu-Zhou Qin; Xian-Wei Mo; Shan-Shan Luo
Journal:  Biomed Res Int       Date:  2020-02-27       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.